Brian J Ball

13PUBLICATIONS
57CO-AUTHORS
Medical infection agents (incl. prions)Medical biochemistry - lipidsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Dec 06, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Kuo-Kai Chin, Brian J Ball, Yasmin Abaza

|May 07, 2025
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study.

Brian J Ball, Rui Song, Enrico Zanardo

|Jan 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL.

Ibrahim Aldoss, Shanpeng Li, Jianying Zhang

|Nov 01, 2024
Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML.

Brian Ball, Wenbin Xiao, Gautam Borthakur

|Jun 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.

Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis

|May 04, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.

Joseph G W McCarter, David Nemirovsky, Christopher A Famulare

Pageof 3

Frequent Collaborators

7 joint publications

Ibrahim Aldoss

5 joint publications

Vinod Pullarkat

5 joint publications

Ryotaro Nakamura

4 joint publications

Hoda Pourhassan